

TABLE OF CONTENTS

	PAGE
ACKNOWLEDGEMENTS	I
ABSTRACT	II
LIST OF TABLES	XI
LIST OF FIGURES	XIV
INTRODUCTION	1
LITERATURE REVIEW	4
A. Interleukin 2 and interleukin 2 receptor	4
1. Properties of interleukin 2	
2. Bioassay of IL-2	
3. IL-2 production	
4. IL-2 receptor expression	
5. Soluble IL _r -2 receptor	
6. Immunoregulatory effect of IL-2	
B. Autorosetting T cells	16
C. Effect of glucocorticoid on immunosuppression	17
1. Effect on leukocyte number	
2. Effect on CMI function	

VIII

	PAGE
D. Systemic lupus erythematosus	19
E. Interleukin 2 and interleukin 2 receptor in SLE patients	27
1. IL-2 production in SLE patients	
2. IL-2 receptor expression in SLE patients	
3. Soluble IL-2 receptor in SLE patients	
MATERIALS AND METHODS	29
A. Subjects	29
B. Cells preparation for assay system	29
1. Preparation of PBMC	
2. Preparation of rested PBMC	
3. Preparation of autologous red blood cells	
C. Assay for IL-2 activity	31
D. Determination of optimum condition for IL-2 production	33
1. Determination of optimum PHA-P concentration	
2. Determination of optimum cells concentration	
3. Determination of optimum incubation time	
E. IL-2 production in vitro	34
F. Standard IL-2 preparation	34
G. Determination of optimum Con A concentration for preparation of AR ⁺ cells	35

	PAGE
H. Preparation of AR ⁺ cells for assay system	37
I. To determine the inability of AR ⁺ cells to absorb IL-2 containing in culture supernatants	38
J. To determine the inability of AR ⁺ cells to decrease PHA-P in culture supernatants	38
K. Comparison between AR ⁺ cells and AR ⁻ cells to suppress IL-2 secretion	39
L. Viability test	40
M. Statistical analysis	40
RESULTS	41
A. Determination of optimum condition for IL-2 production in vitro	41
1. Determination of optimum PHA-P concentration	
2. Determination of optimum cells concentration	
3. Determination of optimum incubation time	
B. Titration of Con A concentration for autorosetting T cells preparation	49
C. To determine the inability of AR ⁺ cells to absorb IL-2 containing in culture supernatants	54

	PAGE
D. To determine the inability of AR ⁺ cells to decrease PHA-P in culture supernatants	56
E. comparison between AR ⁺ cells and AR ⁻ cells to suppress IL-2 secretion	58
F. Comparison between IL-2 production by freshly isolated PBMC	59
G. Comparison between freshly isolated and rested PBMC to produce IL-2	62
H. The percentage of autorosetting T cells of normal subjects and SLE patients	69
I. Suppressive activity of AR ⁺ cells from normal and SLE to suppress IL-2 secretion of autologous rested PBMC	72
J. Suppressive activity of AR ⁺ cells from normal and SLE to suppress IL-2 secretion of heterologous rested normal PBMC	81
DISCUSSION	88
SUMMARY	99
REFERENCES	100
APPENDIX	132
BIOGRAPHY	136

LIST OF TABLES

TABLE		PAGE
1	Properties of Murine, Rat, and Human Interleukin 2.	5
2	Revise criteria for diagnosis of systemic lupus erythematosus.	23
3	IL-2 production by various concentration of PHA-P	42
4	IL-2 production by various concentration of PBMC.	44
5	IL-2 production by various incubation time.	47
6	Optimum con A concentration for preparation of AR ⁺ cells	51
7	Optimum con A concentration for preparation of AR ⁺ cells.	52
8	Effect of AR ⁺ cells absorb IL-2 in culture supernatants	55

TABLE	PAGE
9 Effect of AR ⁺ cells decrease PHA-P in culture supernatants.	57
10 Comparison between AR ⁺ cells and AR ⁻ cells to suppress IL-2 secretion.	59
11 Clinical data of SLE patients.	61
12 Comparison between IL-2 production by freshly isolated PBMC from normal subjects and SLE patients.	63
13 Comparison between freshly isolated and rested PBMC from normal subjects to produce IL-2.	66
14 Comparison between freshly isolated and rested PBMC from SLE patients to produce IL-2.	67
15 The percentage of autorosetting T cells of normal subjects and SLE patients.	70

TABLE		PAGE
16	Suppressive activity of AR ⁺ cells from normal subjects to suppress autologous rested PBMC to secrete IL-2.	75
17	Suppressive activity of AR ⁺ cells from SLE patients to suppress autologous rested PBMC to secrete IL-2.	77
18	Mean percentage of autologous suppression of IL-2 secretion by adding AR ⁺ cells of normal subjects and SLE patients.	79
19	Suppressive activity of AR ⁺ cells from normal subjects to suppress heterologous rested normal PBMC to secrete IL-2.	82
20	Suppressive activity of AR ⁺ cells from SLE patients to suppress heterologous rested normal PBMC to secrete IL-2.	84
21	Mean percentage of heterologous suppression of IL-2 secretion by adding AR ⁺ cells of normal subjects and SLE patients.	86

LIST OF FIGURES

FIGURE		PAGE
1	IL-2 production by various concentration of PHA-P.	43
2	IL-2 production by various concentration of PBMC.	45
3	IL-2 production by various incubation time.	48
4	Optimum con A concentration for preparation of AR ⁺ cells.	53
5	Comparison between AR ⁺ cells and AR ⁻ cells to suppress IL-2 secretion.	60
6	Comparison between IL-2 production by freshly isolated PBMC from normal subjects and SLE patients.	64

FIGURE		PAGE
7	Correlation between IL-2 production by freshly isolated PBMC and disease activity or disease duration of SLE patients.	65
8	Comparison between freshly isolated and rested PBMC from normal subjects and SLE patients to produce IL-2.	68
9	Comparison between % autorsetting T cells of normal subjects and SLE patients.	71
10	Correlation between % autorsetting T cells and disease activity or disease duration of SLE patients.	73
11	Correlation between IL-2 production by freshly isolated PBMC and % autorsetting T cells of SLE patients.	74
12	Suppressive activity of AR ⁺ cells from normal subjects to suppress autologous rested PBMC to secrete IL-2.	76

FIGURE		PAGE
13	Suppressive activity of AR ⁺ cells from SLE patients to suppress autologous rested PBMC to secrete IL-2.	78
14	Mean percentage of autologous suppression of IL-2 secretion by adding AR ⁺ cells of normal subjects and SLE patients.	80
15	Suppressive activity of AR ⁺ cells from normal subjects to suppress heterologous rested normal PBMC to secrete IL-2.	83
16	Suppressive activity of AR ⁺ cells from SLE patients to suppress heterologous rested normal to secrete IL-2.	85
17	Mean percentage of heterologous suppression of IL-2 secretion by adding AR ⁺ cells of normal subjects and SLE patients.	87